Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.54

-3.1%

Nov 18 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2729)	1/30/2001 5:05:26 PM
From: Jibacoa	Read Replies (1) of 52153

IMAT: It seems the market didn't pay any attention to the improved earnings & revenue or the "optimistic" report of the CEO today: ``Sales of EBT scanners are ultimately propelled by growing patient demand for the unique clinical applications offered by Imatron's proprietary technology. During the past 18 months, Imatron has received specific 510(k) market clearances from the Food and Drug Administration (FDA) for electron beam angiography (EBA), low dose lung scanning and EB-Colonography. These clinical applications now offer our customers expanded business opportunities and support the underlying rationale for outpatient 'preventive' imaging centers. As a result, we are now experiencing major growth in the number of multi-system purchasers who are developing national or regional networks of EBT centers. These facilities are dedicated to the early detection of diseases in which early intervention has been demonstrated to be effective in avoiding the catastrophic consequences of waiting until a specific patient has begun to exhibit symptoms. This new paradigm in healthcare delivery is inevitable because of the massive demand created by the 'baby boom' generation as this population group enters the critical 'at risk' age for a wide variety of both serious and treatable diseases. We anticipate that the forces now combining to create and accelerate demand for Imatron's EBT technology will continue to drive revenue and profitability in 2001.'' Well, will watch it, but the "float" is too high <g> Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next